autoimmune

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...

South Korean pharmaceutical company Handok Inc. on Wednesday said it signed a deal with Dutch immunology specialist Argenx to sell the latter's Vyvg...

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...